Portuguese 
Spanish 
Veoza, based on fezolinetant, was approved by Anvisa as a non-hormonal treatment for hot flashes related to menopause
The National Health Surveillance Agency approved the registration of Veoza™ (fezolinetant), a non-hormonal medication indicated for the treatment of moderate to severe vasomotor symptoms associated with menopause.
Commonly known as “hot flashes,” these symptoms appear as sudden waves of intense heat. Additionally, they may be accompanied by sweating and flushing, especially on the head, neck, chest, and upper back.
The authorization was announced by Anvisa on June 23, 2026. The registration is included in Resolution 2,430/2026, published in the Official Gazette of the Union.
-
Giant Phantom Halo Appears Around Remote Pacific Islands, NASA Reveals It’s Created by Tiny Marine Organisms
-
Scientists Develop Method to Store Wind and Solar Energy by Liquefying Air for On-Demand Power Generation
-
Brazilian Engineer Who Grew Up Without Electricity Develops Software, Expands AltoQi to 67,000 Clients, Aiming for $21 Million by Digitizing Brazil’s Construction Industry
-
Spain Launches World’s Largest Floating Dry Dock: 56-Meter Giant Produces Massive Concrete Structures in A Coruña Using Technology Proven in Brazil
Non-hormonal medication approved by Anvisa targets menopause hot flashes
Veoza™ represents a non-hormonal alternative for patients with moderate to severe vasomotor symptoms. The product is aimed at women experiencing hot flashes and night sweats related to menopause.
According to Anvisa, these symptoms are linked to neurological changes in the brain. More specifically, the process involves KNDy neurons, associated with the control of body temperature.
Before menopause, there is a balance between estrogen and neurokinin B. This protein acts in regulating the temperature control center. However, with the drop in estrogen, this balance is altered.
How Veoza works to reduce hot flashes and night sweats
Fezolinetant works by preventing neurokinin B from binding to its targets in the brain. In this way, the medication helps reduce both the number and intensity of hot flashes.
The treatment also acts on night sweats, another common vasomotor symptom during menopause.
This action occurs without the use of hormones. Therefore, the medication was approved as a non-hormonal option for the treatment of these symptoms.
Studies indicated an average reduction of 53% in daily heat waves
The analyzed studies showed results after four weeks of treatment. During this period, the medication reduced, on average, 53% of daily heat waves.
The intensity of symptoms was also lower among women who received Veoza™.
In comparison, the result was different from that observed in the group that received a placebo.
Vasomotor symptoms affect women over 40 years old in different proportions
According to a report by the European Medicines Agency, the global prevalence of vasomotor symptoms associated with menopause ranges from 11% to 47%.
This survey considers women over 40 years old.
Therefore, hot flashes do not represent just an isolated discomfort. They are part of a set of frequent symptoms linked to hormonal and neurological changes of menopause.
Approval is included in a resolution published in the Official Gazette of the Union
Anvisa formalized the approval of the registration of Veoza™ in Resolution 2.430/2026, published in the Official Gazette of the Union.
The agency explained that the medication acts on brain mechanisms related to thermal regulation.
With this, the treatment enters the scenario of non-hormonal medications indicated for moderate to intense vasomotor symptoms associated with menopause.
